These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 18413798)
1. Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature. Cao L; Du P; Jiang SH; Jin GH; Huang QL; Hua ZC Mol Cancer Ther; 2008 Apr; 7(4):851-61. PubMed ID: 18413798 [TBL] [Abstract][Full Text] [Related]
2. Induction of non-small cell lung carcinoma apoptosis using soluble RGD-TRAIL by targeting the integrin receptor of tumor cells. Yao R; Sui A; Wang Z; Liu S; Zhou Q; Liu X; Zhang H Mol Med Rep; 2012 Dec; 6(6):1355-60. PubMed ID: 22965279 [TBL] [Abstract][Full Text] [Related]
3. RGD-avidin-biotin pretargeting to alpha v beta 3 integrin enhances the proapoptotic activity of TNF alpha related apoptosis inducing ligand (TRAIL). Tarrus M; van der Sloot AM; Temming K; Lacombe M; Opdam F; Quax WJ; Molema G; Poelstra K; Kok RJ Apoptosis; 2008 Feb; 13(2):225-35. PubMed ID: 18071905 [TBL] [Abstract][Full Text] [Related]
4. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Shankar S; Chen X; Srivastava RK Prostate; 2005 Feb; 62(2):165-86. PubMed ID: 15389801 [TBL] [Abstract][Full Text] [Related]
5. Smac peptide potentiates TRAIL- or paclitaxel-mediated ovarian cancer cell death in vitro and in vivo. Mao HL; Pang Y; Zhang X; Yang F; Zheng J; Wang Y; Liu P Oncol Rep; 2013 Feb; 29(2):515-22. PubMed ID: 23151974 [TBL] [Abstract][Full Text] [Related]
6. Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade. Das S; Tripathi N; Preet R; Siddharth S; Nayak A; Bharatam PV; Kundu CN Oncotarget; 2017 Jan; 8(1):248-267. PubMed ID: 27542249 [TBL] [Abstract][Full Text] [Related]
7. Dual function of RGD-modified VEGI-192 for breast cancer treatment. Wu J; Jiang Y; Yang W; He Z; Meng S; Zhang Q; Lin M; Zhang H; Li W; Yang Y; Jia Y; Qian L; Lu D; Cai W; Luo G; Wang Y; Zhu X; Li M Bioconjug Chem; 2012 Apr; 23(4):796-804. PubMed ID: 22455451 [TBL] [Abstract][Full Text] [Related]
8. RGD and NGR modified TRAIL protein exhibited potent anti-metastasis effects on TRAIL-insensitive cancer cells in vitro and in vivo. Wang X; Qiao X; Shang Y; Zhang S; Li Y; He H; Chen SZ Amino Acids; 2017 May; 49(5):931-941. PubMed ID: 28236246 [TBL] [Abstract][Full Text] [Related]
9. GMP production and characterization of leucine zipper-tagged tumor necrosis factor-related apoptosis-inducing ligand (LZ-TRAIL) for phase I clinical trial. Jiang J; Liu X; Deng L; Zhang P; Wang G; Wang S; Liu H; Su Y Eur J Pharmacol; 2014 Oct; 740():722-32. PubMed ID: 24929054 [TBL] [Abstract][Full Text] [Related]
10. Blockade of alpha v beta3 and alpha v beta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells. Maubant S; Saint-Dizier D; Boutillon M; Perron-Sierra F; Casara PJ; Hickman JA; Tucker GC; Van Obberghen-Schilling E Blood; 2006 Nov; 108(9):3035-44. PubMed ID: 16835373 [TBL] [Abstract][Full Text] [Related]
11. Improved antitumor activity of TRAIL fusion protein via formation of self-assembling nanoparticle. Huang K; Duan N; Zhang C; Mo R; Hua Z Sci Rep; 2017 Feb; 7():41904. PubMed ID: 28225020 [TBL] [Abstract][Full Text] [Related]
12. RGD-modified polymeric micelles as potential carriers for targeted delivery to integrin-overexpressing tumor vasculature and tumor cells. Wang Y; Wang X; Zhang Y; Yang S; Wang J; Zhang X; Zhang Q J Drug Target; 2009 Jul; 17(6):459-67. PubMed ID: 19527117 [TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand. Fang F; Wang AP; Yang SF Acta Pharmacol Sin; 2005 Nov; 26(11):1373-81. PubMed ID: 16225761 [TBL] [Abstract][Full Text] [Related]
15. A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR. Ren B; Song K; Parangi S; Jin T; Ye M; Humphreys R; Duquette M; Zhang X; Benhaga N; Lawler J; Khosravi-Far R Cancer Res; 2009 May; 69(9):3856-65. PubMed ID: 19366809 [TBL] [Abstract][Full Text] [Related]
16. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide. Yoshimoto M; Ogawa K; Washiyama K; Shikano N; Mori H; Amano R; Kawai K Int J Cancer; 2008 Aug; 123(3):709-15. PubMed ID: 18498129 [TBL] [Abstract][Full Text] [Related]
17. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction. Zhou L; Wang W; Dicker DT; Humphreys RC; El-Deiry WS Cancer Biol Ther; 2011 Aug; 12(4):335-48. PubMed ID: 21785270 [TBL] [Abstract][Full Text] [Related]
18. RGD-labeled USPIO inhibits adhesion and endocytotic activity of alpha v beta3-integrin-expressing glioma cells and only accumulates in the vascular tumor compartment. Kiessling F; Huppert J; Zhang C; Jayapaul J; Zwick S; Woenne EC; Mueller MM; Zentgraf H; Eisenhut M; Addadi Y; Neeman M; Semmler W Radiology; 2009 Nov; 253(2):462-9. PubMed ID: 19789239 [TBL] [Abstract][Full Text] [Related]
19. Caspase-8 Acts in a Non-enzymatic Role as a Scaffold for Assembly of a Pro-inflammatory "FADDosome" Complex upon TRAIL Stimulation. Henry CM; Martin SJ Mol Cell; 2017 Feb; 65(4):715-729.e5. PubMed ID: 28212752 [TBL] [Abstract][Full Text] [Related]
20. Caspase-8 activation by TRAIL monotherapy predicts responses to IAPi and TRAIL combination treatment in breast cancer cell lines. Polanski R; Vincent J; Polanska UM; Petreus T; Tang EK Cell Death Dis; 2015 Oct; 6(10):e1893. PubMed ID: 26426685 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]